|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
JPS5283918A
(en)
*
|
1976-01-01 |
1977-07-13 |
Wellcome Found |
Pharmaceutical composition
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
JPS5777697A
(en)
|
1980-11-04 |
1982-05-15 |
Nippon Zoki Pharmaceut Co Ltd |
Physiologically active substance nsq
|
|
US4328245A
(en)
|
1981-02-13 |
1982-05-04 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
|
US4410545A
(en)
|
1981-02-13 |
1983-10-18 |
Syntex (U.S.A.) Inc. |
Carbonate diester solutions of PGE-type compounds
|
|
JPS57209225A
(en)
|
1981-06-18 |
1982-12-22 |
Yamasa Shoyu Co Ltd |
Antitumor activity intensifier
|
|
US4409239A
(en)
|
1982-01-21 |
1983-10-11 |
Syntex (U.S.A.) Inc. |
Propylene glycol diester solutions of PGE-type compounds
|
|
JPS6028987A
(ja)
*
|
1983-07-28 |
1985-02-14 |
Chugai Pharmaceut Co Ltd |
新規ジゴキシン誘導体
|
|
HU196714B
(en)
|
1984-10-04 |
1989-01-30 |
Monsanto Co |
Process for producing non-aqueous composition comprising somatotropin
|
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
US5612059A
(en)
|
1988-08-30 |
1997-03-18 |
Pfizer Inc. |
Use of asymmetric membranes in delivery devices
|
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
PH30995A
(en)
|
1989-07-07 |
1997-12-23 |
Novartis Inc |
Sustained release formulations of water soluble peptides.
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
US5585112A
(en)
|
1989-12-22 |
1996-12-17 |
Imarx Pharmaceutical Corp. |
Method of preparing gas and gaseous precursor-filled microspheres
|
|
IT1246382B
(it)
|
1990-04-17 |
1994-11-18 |
Eurand Int |
Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
|
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
|
US5204329A
(en)
|
1990-06-11 |
1993-04-20 |
Du Pont Merck Pharmaceutical Company |
Treatment of organ transplantation rejection
|
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
TW333456B
(en)
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
US6274552B1
(en)
|
1993-03-18 |
2001-08-14 |
Cytimmune Sciences, Inc. |
Composition and method for delivery of biologically-active factors
|
|
US5985307A
(en)
|
1993-04-14 |
1999-11-16 |
Emory University |
Device and method for non-occlusive localized drug delivery
|
|
US5523092A
(en)
|
1993-04-14 |
1996-06-04 |
Emory University |
Device for local drug delivery and methods for using the same
|
|
US6087324A
(en)
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
|
US6004534A
(en)
|
1993-07-23 |
1999-12-21 |
Massachusetts Institute Of Technology |
Targeted polymerized liposomes for improved drug delivery
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
US5759542A
(en)
|
1994-08-05 |
1998-06-02 |
New England Deaconess Hospital Corporation |
Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
|
|
US5660854A
(en)
|
1994-11-28 |
1997-08-26 |
Haynes; Duncan H |
Drug releasing surgical implant or dressing material
|
|
US6316652B1
(en)
|
1995-06-06 |
2001-11-13 |
Kosta Steliou |
Drug mitochondrial targeting agents
|
|
US5798119A
(en)
|
1995-06-13 |
1998-08-25 |
S. C. Johnson & Son, Inc. |
Osmotic-delivery devices having vapor-permeable coatings
|
|
AU6242096A
(en)
|
1995-06-27 |
1997-01-30 |
Takeda Chemical Industries Ltd. |
Method of producing sustained-release preparation
|
|
TW448055B
(en)
|
1995-09-04 |
2001-08-01 |
Takeda Chemical Industries Ltd |
Method of production of sustained-release preparation
|
|
JP2909418B2
(ja)
|
1995-09-18 |
1999-06-23 |
株式会社資生堂 |
薬物の遅延放出型マイクロスフイア
|
|
US6039975A
(en)
|
1995-10-17 |
2000-03-21 |
Hoffman-La Roche Inc. |
Colon targeted delivery system
|
|
US5980945A
(en)
|
1996-01-16 |
1999-11-09 |
Societe De Conseils De Recherches Et D'applications Scientifique S.A. |
Sustained release drug formulations
|
|
TW345603B
(en)
|
1996-05-29 |
1998-11-21 |
Gmundner Fertigteile Gmbh |
A noise control device for tracks
|
|
US6264970B1
(en)
|
1996-06-26 |
2001-07-24 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
|
US6419961B1
(en)
|
1996-08-29 |
2002-07-16 |
Takeda Chemical Industries, Ltd. |
Sustained release microcapsules of a bioactive substance and a biodegradable polymer
|
|
ZA977967B
(en)
|
1996-09-23 |
1999-03-04 |
Lilly Co Eli |
Combination therapy for treatment of psychoses
|
|
HUP0000116A3
(en)
|
1996-10-01 |
2000-08-28 |
Stanford Res Inst Int |
Taste-masked microcapsule compositions and methods of manufacture
|
|
CA2217134A1
(en)
|
1996-10-09 |
1998-04-09 |
Sumitomo Pharmaceuticals Co., Ltd. |
Sustained release formulation
|
|
DE69730093T2
(de)
|
1996-10-31 |
2006-07-20 |
Takeda Pharmaceutical Co. Ltd. |
Zubereitung mit verzögerter Freisetzung
|
|
US6131570A
(en)
|
1998-06-30 |
2000-10-17 |
Aradigm Corporation |
Temperature controlling device for aerosol drug delivery
|
|
WO1998027980A2
(en)
|
1996-12-20 |
1998-07-02 |
Takeda Chemical Industries, Ltd. |
Method of producing a sustained-release preparation
|
|
US5891474A
(en)
|
1997-01-29 |
1999-04-06 |
Poli Industria Chimica, S.P.A. |
Time-specific controlled release dosage formulations and method of preparing same
|
|
US6120751A
(en)
|
1997-03-21 |
2000-09-19 |
Imarx Pharmaceutical Corp. |
Charged lipids and uses for the same
|
|
US6060082A
(en)
|
1997-04-18 |
2000-05-09 |
Massachusetts Institute Of Technology |
Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
|
|
US6350458B1
(en)
|
1998-02-10 |
2002-02-26 |
Generex Pharmaceuticals Incorporated |
Mixed micellar drug deliver system and method of preparation
|
|
US6613358B2
(en)
|
1998-03-18 |
2003-09-02 |
Theodore W. Randolph |
Sustained-release composition including amorphous polymer
|
|
US6048736A
(en)
|
1998-04-29 |
2000-04-11 |
Kosak; Kenneth M. |
Cyclodextrin polymers for carrying and releasing drugs
|
|
KR19990085365A
(ko)
|
1998-05-16 |
1999-12-06 |
허영섭 |
지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
|
|
AU1321900A
(en)
|
1998-10-23 |
2000-05-15 |
Sepracor, Inc. |
Compositions and methods employing r(-) fluoxetine and other active ingredients
|
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
US6271359B1
(en)
|
1999-04-14 |
2001-08-07 |
Musc Foundation For Research Development |
Tissue-specific and pathogen-specific toxic agents and ribozymes
|
|
AP2001002264A0
(en)
|
2000-08-30 |
2001-09-30 |
Pfizer Prod Inc |
Sustained release formulations for growth hormone secretagogues.
|
|
WO2003099011A1
(en)
*
|
2002-05-28 |
2003-12-04 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
|
|
AU2003272608A1
(en)
|
2002-09-19 |
2004-04-08 |
University Of Utah Research Foundation |
Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease
|
|
US7230097B2
(en)
|
2003-03-10 |
2007-06-12 |
Lupin Ltd. |
Process for preparation of 7-[α-Amino (4-hydroxyphenyl) acetamido]-3-substituted-3-cephem-4-carboxylic acid
|
|
GB0307259D0
(en)
|
2003-03-28 |
2003-05-07 |
Glaxo Group Ltd |
Process
|
|
GB2410947B
(en)
*
|
2004-02-11 |
2008-09-17 |
Cambridge Lab Ltd |
Pharmaceutical compounds
|
|
TW201422238A
(zh)
|
2004-06-04 |
2014-06-16 |
Genentech Inc |
Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
|
|
EP1799865B1
(en)
|
2004-09-30 |
2012-06-06 |
Vanda Pharmaceuticals Inc. |
Methods for the administration of iloperidone
|
|
ATE415973T1
(de)
*
|
2004-10-28 |
2008-12-15 |
Wyeth Corp |
Gemeinsame gabe von tigecyclin und digoxin
|
|
WO2006053067A2
(en)
|
2004-11-09 |
2006-05-18 |
Prestwick Pharmaceuticals, Inc. |
Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
|
|
EP1855677B1
(en)
|
2005-08-06 |
2008-12-03 |
Cambridge Laboratories (Ireland) Limited |
3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
|
|
US20100076087A1
(en)
|
2005-10-06 |
2010-03-25 |
Auspex Pharmaceuticals, Inc. |
Methods of reduction of interpatient variability
|
|
PL2081929T3
(pl)
|
2006-11-08 |
2013-06-28 |
Neurocrine Biosciences Inc |
Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania
|
|
GB0721669D0
(en)
|
2007-11-02 |
2007-12-12 |
Cambridge Lab Ireland Ltd |
Pharmaceutical compounds
|
|
RU2476431C2
(ru)
|
2008-01-18 |
2013-02-27 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Конденсированное производное аминодигидротиазина
|
|
US20110053866A1
(en)
|
2008-08-12 |
2011-03-03 |
Biovail Laboratories International (Barbados) S.R.L. |
Pharmaceutical compositions
|
|
GB2462611A
(en)
|
2008-08-12 |
2010-02-17 |
Cambridge Lab |
Pharmaceutical composition comprising tetrabenazine
|
|
GB2463451A
(en)
|
2008-09-08 |
2010-03-17 |
Cambridge Lab |
3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
|
|
GB2463452A
(en)
|
2008-09-08 |
2010-03-17 |
Cambridge Lab |
Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
|
|
WO2010044981A2
(en)
|
2008-09-18 |
2010-04-22 |
Auspex Pharmaceutical ,Inc. |
Benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
US20100096319A1
(en)
|
2008-10-17 |
2010-04-22 |
General Electric Company |
Separator assembly
|
|
CN102292094B
(zh)
|
2009-01-20 |
2013-08-14 |
洛杉矶生物医学研究所在哈伯-加州大学洛杉矶分校医疗中心 |
增强神经药方疗效的山梨酸与苯甲酸及其衍生物
|
|
US8999638B2
(en)
|
2009-04-06 |
2015-04-07 |
Vanda Pharmaceuticals, Inc. |
Method of treatment based on polymorphisms of the KCNQ1 gene
|
|
CA2771539A1
(en)
|
2009-08-12 |
2011-02-17 |
Valeant International (Barbados) Srl |
Pharmaceutical compositions with tetrabenzine
|
|
CA2801061A1
(en)
|
2010-06-01 |
2011-12-08 |
Auspex Pharmaceuticals, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
WO2012000308A1
(zh)
|
2010-06-29 |
2012-01-05 |
中国药科大学 |
丁苯那嗪的拆分方法
|
|
WO2012012542A1
(en)
|
2010-07-20 |
2012-01-26 |
Cyrenaic Pharmaceuticals, Inc. |
Methods of use of cyclic amide derivatives to treat schizophrenia
|
|
WO2012153341A1
(en)
|
2011-05-12 |
2012-11-15 |
Arch Pharmalabs Limited |
A process for the preparation of iloperidone and pharmaceutically acceptable salts thereof
|
|
CN104684555A
(zh)
|
2012-09-18 |
2015-06-03 |
奥斯拜客斯制药有限公司 |
囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
|
|
KR102148990B1
(ko)
|
2012-12-18 |
2020-08-27 |
반다 파마슈티칼즈, 인코퍼레이티드. |
일주기 리듬 장애의 치료
|
|
EA202091397A1
(ru)
|
2013-01-31 |
2020-09-04 |
Ауспекс Фармацетикалс, Инк. |
Бензохинолоновые ингибиторы vmat2
|
|
JP6476174B2
(ja)
|
2013-06-19 |
2019-02-27 |
ソム イノヴェーション バイオテック、ソシエダッド リミターダ |
運動過剰障害の予防および／または治療における使用のための治療剤
|
|
US20150133460A1
(en)
|
2013-11-11 |
2015-05-14 |
Millennium Phamaceuticals, Inc. |
Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
|
|
WO2015077521A1
(en)
|
2013-11-22 |
2015-05-28 |
Auspex Pharmaceuticals, Inc. |
Benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
IL305990B2
(en)
|
2013-12-03 |
2025-12-01 |
Intra Cellular Therapies Inc |
Long-acting injectable composition comprising polymeric microspheres of heterocycle fused gamma-carboline compounds or a pharmaceutical composition for sustained or delayed release comprising the compounds and their use in the treatment of bipolar disorder i and/or bipolar ii disorder
|
|
EA201691512A1
(ru)
|
2014-01-27 |
2017-01-30 |
Оспекс Фармасьютикалз, Инк. |
Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2
|
|
NZ760790A
(en)
|
2014-02-07 |
2022-11-25 |
Neurocrine Biosciences Inc |
Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
|
|
US10166183B2
(en)
|
2014-02-07 |
2019-01-01 |
Auspex Pharmaceuticals, Inc. |
Pharmaceutical formulations
|
|
WO2015171802A1
(en)
*
|
2014-05-06 |
2015-11-12 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
|
|
CA2974540C
(en)
|
2015-02-06 |
2023-09-26 |
Neurocrine Biosciences, Inc. |
[9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
|
|
HRP20221106T1
(hr)
|
2015-03-06 |
2022-11-25 |
Auspex Pharmaceuticals, Inc. |
Postupci liječenja abnormalnih nevoljnih poremećaja pokreta
|
|
EA036837B1
(ru)
|
2015-06-23 |
2020-12-25 |
Нейрокрин Байосайенсиз, Инк. |
Ингибиторы vmat2 для лечения неврологических заболеваний или расстройств
|
|
MY193767A
(en)
*
|
2015-10-30 |
2022-10-27 |
Neurocrine Biosciences Inc |
Valbenazine salts and polymorphs thereof
|
|
EP3377046A1
(en)
|
2015-11-17 |
2018-09-26 |
Rontis Hellas S.A. |
Pharmaceutical composition containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
|
|
CN108925135B
(zh)
|
2015-12-23 |
2025-09-19 |
纽罗克里生物科学有限公司 |
制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
|
|
TW202345829A
(zh)
|
2016-12-02 |
2023-12-01 |
美商紐羅克里生物科學有限公司 |
戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
|
|
WO2018140092A1
(en)
|
2017-01-27 |
2018-08-02 |
Obrien Christopher F |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
JP7250692B2
(ja)
|
2017-04-01 |
2023-04-03 |
アデプティオ ファーマシューティカルズ リミテッド |
運動障害の治療における使用のためのジヒドロテトラベナジン
|
|
CN110678181A
(zh)
|
2017-04-01 |
2020-01-10 |
阿德普蒂奥制药有限公司 |
(+)-α-二氢丁苯那嗪在治疗运动障碍中的用途
|
|
JOP20190239A1
(ar)
|
2017-04-19 |
2019-10-09 |
Neurocrine Biosciences Inc |
مركبات مثبطة لـ vmat2 وتركيبات منها
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
ES3024958T3
(en)
|
2017-09-21 |
2025-06-05 |
Neurocrine Biosciences Inc |
High dosage valbenazine formulation and compositions, methods, and kits related thereto
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
JP2021502959A
(ja)
|
2017-10-10 |
2021-02-04 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
特定のｖｍａｔ２インヒビターを投与するための方法
|
|
MX2020013004A
(es)
|
2018-06-14 |
2021-02-17 |
Neurocrine Biosciences Inc |
Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
|
|
SG11202100303QA
(en)
|
2018-08-15 |
2021-02-25 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
MA55893A
(fr)
|
2019-05-09 |
2022-03-16 |
Neurocrine Biosciences Inc |
Procédés d'administration de certains inhibiteurs de vmat2
|
|
US10689380B1
(en)
|
2019-07-30 |
2020-06-23 |
Farmhispania S.A. |
Crystalline forms of valbenazine ditosylate
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
JP2022547990A
(ja)
|
2019-09-13 |
2022-11-16 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
バルベナジンの合成のための方法
|